[Individual sensitivity of ovarian ascitic cancer to thiophosphamide].
D000225:Adenine / Q000378:metabolism; D000230:Adenocarcinoma / Q000188:drug therapy; D001201:Ascites / Q000188:drug therapy*; D001202:Ascitic Fluid / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D002250:Carbon Radioisotopes; D002277:Carcinoma / Q000188:drug therapy; D002291:Carcinoma, Papillary / Q000188:drug therapy; D004273:DNA, Neoplasm / Q000378:metabolism; D004351:Drug Resistance; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012334:RNA, Neoplasm / Q000378:metabolism; D013852:Thiotepa / Q000627:therapeutic use*
D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D013852:Thiotepa; D000225:Adenine
Individual'naia chuvstvitel'nost' astsitnogo raka iaichnikov k tiofosfamidu